Inmune Bio, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
David Moss (CEO) and Cory Ellspermann (CFO) certified the June 30, 2026 quarterly report on August 6, 2026, attesting to accuracy of financial statements, effectiveness of disclosure controls and internal controls over financial reporting, and compliance with SEC requirements under SOX 302 and 906.
Why this rating
Standard SOX certification exhibits; routine quarterly compliance filing with no material operational, financial, or strategic disclosures.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.